UBS downgrades Novo Nordisk, cites 'rapidly deteriorating growth' in GLP-1 market

UBS downgraded Novo Nordisk to Neutral from Buy, slashing its price target by 43% to $52.55, citing concerns over Ozempic's inability to regain market leadership against Eli Lilly's GLP-1 drugs and poor commercial execution leading to stagnating growth in Novo's key anti-obesity portfolio. Analyst Matthew Weston highlighted a rapidly deteriorating growth profile and significant concentration risk, despite Novo's strong brand recognition. This downgrade follows Novo Nordisk's ADRs plummeting over 43% year-to-date and recent full-year guidance cuts, signaling a loss of confidence in its GLP-1 strategy and execution, though its diabetes market leadership remains unchallenged.

Analysis

A UBS analyst has downgraded Novo Nordisk (NVO) to Neutral from Buy, executing a significant 43% cut to the 12-month price target, now set at $52.55. The core of this bearish thesis is the assessment that Novo's GLP-1 franchise, led by Ozempic, is decisively losing market share to Eli Lilly's (LLY) tirzepatide-based drugs and is unlikely to regain its leadership position. The analyst report points to a "rapidly deteriorating growth profile" and "stagnated" growth for Novo's key portfolio, which is particularly concerning given the significant unmet medical need in the anti-obesity market. This market share loss is attributed not to an inferior product but to "poor commercial execution" and a clear preference from both doctors and patients for Lilly's Mounjaro and Zepbound. The downgrade is further substantiated by Novo's own recent actions, including a full-year guidance cut for its Wegovy drug and a CEO change, as well as the stock's more than 43% year-to-date decline. Additional headwinds cited include uncertain sales outlook due to GLP-1 compounders and the risk that potential Medicare reimbursement could be coupled with price controls that would "significantly reduce value." While the report is highly critical of the GLP-1 strategy, it maintains that Novo's leadership in the broader diabetes market remains secure due to its established insulin portfolio.

Key Decisions for Investors

• Given the documented market share loss to Eli Lilly and concerns over poor commercial execution, investors should critically reassess bullish positions on Novo Nordisk, as its primary growth driver is under significant competitive pressure.
• The analysis positions Eli Lilly as the clear victor in the GLP-1 obesity drug segment, suggesting investors could consider LLY for exposure to this high-growth market or explore a pairs trade (long LLY, short NVO) to capitalize on this competitive dynamic.
• For current Novo Nordisk shareholders, it is crucial to monitor for signs of a turnaround in commercial strategy under the new CEO and any improvements in sales traction within insured channels, as these are the key weaknesses highlighted in the report.
• Investors should distinguish between the challenged outlook for Novo's anti-obesity franchise and its stable, market-leading diabetes business, as the stock's future performance will depend on whether the latter can offset the significant headwinds in the former.